{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021986","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.976762+00:00","generated_at":"2026-06-15T01:32:40.552776+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Terns Pharma Q1 net loss $21.5M; cash $298M; clinical milestones on track for 2023","bullets":["Net loss $21.5M ($0.31/share) vs $13.8M ($0.55/share) in Q1 2022; R&D spend rose to $17.1M from $8.1M.","Cash, equivalents and marketable securities $297.5M as of Mar 31, 2023, providing runway into 2026.","TERN-501 Phase 2a NASH data (DUET trial) expected Q3 2023; TERN-701 US CML trial to start H2 2023.","TERN-601 (GLP-1) Phase 1 obesity trial on track for H2 2023 with initial data in 2024.","Appointed Emil Kuriakose, M.D. as Chief Medical Officer of Oncology in May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021986","json":"https://secwatch.observer/filing/0000950170-23-021986.json","markdown":"https://secwatch.observer/filing/0000950170-23-021986.md","text":"https://secwatch.observer/filing/0000950170-23-021986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023021986/0000950170-23-021986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023021986/tern-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:32:40.552776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbcfcf8b0a1bc9d87331815802b4b15802f91144","claim":"Terns Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss was $21.5 million, EPS Net loss per share, basic and diluted $ (0.31).","evidence_excerpt":"Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today reported financial results for the first quarter ended March 31, 2023 and corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023021986/0000950170-23-021986-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $21.5 million"},{"label":"EPS","value":"Net loss per share, basic and diluted $ (0.31)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}